An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development

Bibliography

• BIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al: Progress report on new anti-epileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res. (1999) 34:1–41.
   PubMed Web of Science ®Google Scholar
• ••Source of information about drugs in development forepilepsy.
   Google Scholar
• ROGAWSKI MA, LE DQ, UYAKUL D et al.: Anticonvulsant efficacy of ADCI (5-aminocarbony1-10,11-dihydro-5H-dibenzok,clicyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia (1995) 36:566–571.
   PubMed Web of Science ®Google Scholar
• SIGEL E, BAUR R, NETZER R et al:The anti-epileptic drug AWD 131-138 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. Neurosci. Lett. (1998) 245:85–88.
   PubMed Web of Science ®Google Scholar
• KOZAK A, DOLINA S, KAMBURG S et al: DP-VPA, a novelprodrug of VPA has enhanced protective effect in genetically epilepsy-prone mice. Soc. Neurosci. (1997) 23 (2):2163.
   Google Scholar
• MONAGHAN EP, NAVALTA LA, SHUM L et al.: Initialhuman experience with ganaxolone, a neuroactive steroid with anti-epileptic activity. Epilepsia (1997) 38:1026–1031.
   PubMed Web of Science ®Google Scholar
• PATSALOS PN: Pharmacokinetic profile of leveti-racetam: towards ideal characteristics. Pharmacology & Therapeutics (2000) (In Press).
   Google Scholar
• JONES FA, DAVIES JA: The anticonvulsant effects of the enantiomers of losigamone. Br. J. Pharmacol (1999) 128:1223–1228.
   PubMed Web of Science ®Google Scholar
• BIBER A, DIENEL A: Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers. Int. J. Clin. Pharmacol. Ther. (1996) 34:6–11.
   PubMed Web of Science ®Google Scholar
• BRYANS JS, WUSTROW DJ: 3-substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. (1999) 19:149–177.
   PubMed Web of Science ®Google Scholar
• DAVIES JA: Remacemide hydrochloride: a novel anti-epileptic agent. Gen. Pharmacol. (1997) 28:499–502.
   PubMedGoogle Scholar
• RUNDFELDT C: The new anticonvulsant retigabine (D-23129) acts as an opener of K± channels in neuronal cells. Eur. J. Pharmacol. (1997) 336:243–249
   PubMed Web of Science ®Google Scholar
• BLOTNIK S, BERGMAN F, BIALER M: The disposition of valproyl glycinamide and valproyl glycine in rats. Pharmacol. Res. (1997) 14:873–878.
   Web of Science ®Google Scholar
• MAURIZIS JC, MADELMONT JC, RAPP M et al.:Disposition and metabolism of 2,6-dimethylbenzamide n-(5-methyl-3-isoxazoly1) (D2916) in male and female rats. Drug Metab. Dispos. (1997) 25:33–39.
   PubMed Web of Science ®Google Scholar
• JAIN KK: Drug Delivery to the Central Nervous System.Decision Resources Inc, Waltham, Massachusetts, USA (2000).
   Google Scholar
• •Discussion of the issues of drug delivery with a section on anti-epileptic drugs.
   Google Scholar
• FREESE A, KAPLITT MG, O'CONNOR WM et al.: Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implica-tions for a gene therapy approach to epilepsy. Epilepsia (1997) 38:759–766.
   Google Scholar
• JAIN KK: Textbook of Gene Therapy. Hogrefe & Huber, Gottingen-Bern-Seattle, 1998.
   Google Scholar
• KAPEGHIAN JC, MADAN A, PARKINSON A et al.: Evalua-tion of rufinamide (CGP 33101), a novel anticonvul-sant, for potential drug interactions in vitro. Epilepsia (1996) 37 (Suppl. 5):26 (Abstract).
   Google Scholar
• STABLES JP, BIALER M, JOHANNESSEN SI et al.: Progress report on new anti-epileptic drugs. A summary of the Second Eilat Conference. Epilepsy Res. (1995) 22:235–246.
   PubMed Web of Science ®Google Scholar
• SCHMUTZ M, ALLGEIER H, JEKER A et al: Anticonvulsantprofile of CGP 33101 in animals. Epilepsia (1993) 34 (Suppl. 2):122 (Abstract).
   Google Scholar
• •The only published source of preclinical pharmacology. A more recent full paper in preparation by the authors.
   Google Scholar
• WALDMEIER F, GSCHWIND HP, ROUAN MC et al.: Metabolism of the new anticonvulsive trial drug rufinamide (CGP 33101) in healthy male volunteers Epilepsia (1996) 37 (Suppl. 5):167 (Abstract).
   Google Scholar
• CHEUNG WK, KIANIFARD F, WONG A et al.: Intra- andinter-subject variabilities of CGP 33101 after replicate single oral doses of two 200-mg Tablets and 400-mg suspension. Pharm. Res. (1995) 12:1878–1882.
   PubMed Web of Science ®Google Scholar
• CARDOT JM, LECAILLON JB, CZENDLIK C et al.:: The influence of food on the disposition of the anti-epileptic rufinamide in healthy volunteers. Biopharm. Drug Dispos. (1998) 19:259–262.
   PubMed Web of Science ®Google Scholar
• CHANG S-W, CHOI L, KAROLCHYK MA et al.: A pharma-cokinetic evaluation of rufinamide in elderly and younger subjects. Epilepsia (1998) 39\(Suppl. 6):59 (Abstract).
   Google Scholar
• SACHDEO RC, CHOI L, YEH C-M et al.: Pharmacokinetic and safety in adjunctive rufinamide therapy in pediatric patients with epilepsy. Epilepsia (1998) 39 (Suppl. 6):166 (Abstract).
   Google Scholar
• SVENDSEN KD, CHOI L, CHEN B-L et al.: Single-center, open-label, multiple dose, pharmacokinetic trial investigating the effect of rufinamide administration on ortho-Novum 1/35 in healthy women. Epilepsia (1998) 39 (Suppl. 6)59 (Abstract).
   Google Scholar
• PALHAGEN S, CANGER R, HENRIKSEN 0 et al.: Efficacy and safety of rufinamide in patients with refractory epilepsy. Epilepsia (1997) 38 (Suppl. 8):207–208.
   Google Scholar
• LITZINGER MJ, ANNAJILL H: Safety and efficacy of open-label rufinamide as adjunctive therapy in paediatric patients with partial seizures. Epilepsia (1999) 40 (Suppl. 7):114 (Abstract).
   Google Scholar
• PERUCCA E, BIALER M: The clinical pharmacokinetics of the newer anti-epileptic drugs. Focus on topira-mate, zonisamide and tiagabine. Clinical Pharmacoki-netics (1996) 31:29–46.
   PubMed Web of Science ®Google Scholar